ABSTRACT
Followinginitialscreeningprocedures, potential subjects entered a I-week, single-blind, placebo run-in period, after which a baseline Clinical Global Impression (CG!) Global Improvement rating was perfonned. Patients who were rated no more than minimally improved (CG! Global Improvement rating >2) and who continued to meet all inclusion cdtena were randomized to receive paroxetine or placebo (identical in appearance). Patients were randomly assigned in a balanced fashion to the 2 treatment groups
~30 If.
